Business
Castle Biosciences' DecisionDx®-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at AAD 2026
Data from 1,868 Surveillance, Epidemiology and End Results (SEER)-linked patients show DecisionDx-Melanoma significantly stratifies five-year
About this update from Castle Biosciences, Inc.
[{"type":"text","content":"Data from 1,868 Surveillance, Epidemiology and End Results (SEER)-linked patients show DecisionDx-Melanoma significantly stratifies five-year melanoma-specific survival within American Joint Committee on Cancer (AJCC) stages and T categories, identifying patients whose mortality risk is substantially higher or lower than staging alone would predictFRIENDSWOOD, Texas, March 27, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will present new data at the 2026 American Academy of Dermatology (AAD) Annual Meeting, taking place March 27–31 in Denver, demonstrating that its DecisionDx-Melanoma test refines mortality risk within AJCC stages for patients with cutaneous melanoma (CM). The data show that DecisionDx-Melanoma identifies clinically meaningful differences in mortality risk among patients within the same stage, which may help clinicians more confidently escalate care for higher-risk patients while avoiding unnecessary interventions in those at lower risk of poor outcomes.\n \n \n \n \n \n \n \n\"The findings being presented at AAD reinforce that staging alone does not tell the whole story,\" said Harrison Nguyen M.D., MBA, MPH, lead study author and double board-certified dermatologist and fellowship-trained Mohs micrographic surgeon. \"Incorporating DecisionDx-Melanoma into routine risk assessment provides physicians with biologic information that complements staging and supports more personalized management decisions, helping to identify patients who may warrant closer monitoring or earlier intervention, while also recognizing those who may be safely managed less intensively.\"Detailed findings from this analysis will be presented in the following poster at AAD:ePoster: 76747 – The 31-GEP provides actionable risk stratification of 5-year melanoma specific survival rates within AJCC subgroupsLead Author: Harrison Nguyen M.D., MBA, MPH, Harrison Dermatology & Research Group, Missouri City, TexasThis poster from Castle's ongoing collaboration leveraging data from the National Cancer Institute's SEER Program registries evaluates risk stratification using the DecisionDx-Melanoma test in patients with CM across T categories and AJCC stages.Traditional AJCC staging groups biologically distinct tumors based on clinicopathologic features alone,...